Biotech is a topic tracked in our intelligence system with 5 linked articles.
EPFL's Integrated Neurotechnologies Lab unveiled LogSync, a sub-200-microwatt implantable neural system-on-chip that decodes cross-region brain synchrony to classify cognitive/emotional states and trigger adaptive deep-brain-stimulation, funded by a CHF 6.6M NIMH grant and tied to EPFL spin-off Infera Neuro.
STAT+'s Day 2 ESMO 2026 dispatch from Madrid covers the heavily anticipated detailed presentation of Merck/Moderna's intismeran melanoma cancer vaccine data plus new combination data for Amgen's Imdelltra and AstraZeneca's Imfinzi in extensive-stage small cell lung cancer.
An ESMO scorecard analysis covered by STAT finds only 31% of 97 EMA-approved cancer drug indications (Jan 2022–Jul 2026) delivered high clinical benefit, with over half of the 30 high-benefit indications concentrated in five drugmakers — four of them Chinese or Japanese — signaling a structural shift in where oncology innovation value is being created.
A patient death in Bristol Myers Squibb's Phase 1 multiple sclerosis CAR-T trial deepens the emerging safety crisis in autoimmune CAR-T therapy, following three deaths already disclosed by Novartis.
STAT's on-the-ground ESMO 2026 newsletter reports that the conference's most anticipated readout — Moderna and Merck's melanoma cancer vaccine (intismeran) — was upended by an embargo violation on the eve of the meeting, with companion coverage confirming the therapy met key endpoints and highlighting an 82% response rate for Tango's pancreatic cancer combo.
Novartis' remibrutinib cut annualized MS relapse rates by 35.2% and 31.2% vs Sanofi's Aubagio in twin Phase 3 REMODEL trials — clearly trailing Roche's fenebrutinib (>50% reduction) but differentiating on a cleaner safety profile that keeps it commercially viable.
Subscribe for real-time topic updates and unlimited access to our intelligence platform.